OSE Immunotherapeutics Statistics
Total Valuation
OSE Immunotherapeutics has a market cap or net worth of GBP 118.76 million. The enterprise value is 91.81 million.
Market Cap | 118.76M |
Enterprise Value | 91.81M |
Important Dates
The last earnings date was Wednesday, January 1, 2025.
Earnings Date | Jan 1, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | +22.97% |
Shares Change (QoQ) | +22.87% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 16.45M |
Valuation Ratios
The trailing PE ratio is 3.04.
PE Ratio | 3.04 |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | n/a |
P/TBV Ratio | 1.72 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.02, with an EV/FCF ratio of 1.86.
EV / Earnings | 2.35 |
EV / Sales | 1.30 |
EV / EBITDA | 2.02 |
EV / EBIT | 2.02 |
EV / FCF | 1.86 |
Financial Position
The company has a current ratio of 4.93, with a Debt / Equity ratio of 0.54.
Current Ratio | 4.93 |
Quick Ratio | 4.70 |
Debt / Equity | 0.54 |
Debt / EBITDA | 0.82 |
Debt / FCF | 0.75 |
Interest Coverage | 18.48 |
Financial Efficiency
Return on equity (ROE) is 88.54% and return on invested capital (ROIC) is 35.12%.
Return on Equity (ROE) | 88.54% |
Return on Assets (ROA) | 30.41% |
Return on Capital (ROIC) | 35.12% |
Revenue Per Employee | 1.36M |
Profits Per Employee | 750,516 |
Employee Count | 55 |
Asset Turnover | 0.75 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +73.69% in the last 52 weeks. The beta is 0.96, so OSE Immunotherapeutics's price volatility has been similar to the market average.
Beta (5Y) | 0.96 |
52-Week Price Change | +73.69% |
50-Day Moving Average | 8.24 |
200-Day Moving Average | 6.90 |
Relative Strength Index (RSI) | 34.33 |
Average Volume (20 Days) | 104 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OSE Immunotherapeutics had revenue of GBP 70.74 million and earned 39.03 million in profits. Earnings per share was 1.71.
Revenue | 70.74M |
Gross Profit | 70.74M |
Operating Income | 45.65M |
Pretax Income | 41.91M |
Net Income | 39.03M |
EBITDA | 44.90M |
EBIT | 45.65M |
Earnings Per Share (EPS) | 1.71 |
Balance Sheet
The company has 64.22 million in cash and 37.21 million in debt, giving a net cash position of 27.01 million.
Cash & Cash Equivalents | 64.22M |
Total Debt | 37.21M |
Net Cash | 27.01M |
Net Cash Per Share | n/a |
Equity (Book Value) | 69.05M |
Book Value Per Share | 3.17 |
Working Capital | 57.99M |
Cash Flow
In the last 12 months, operating cash flow was 49.48 million and capital expenditures -28,826, giving a free cash flow of 49.45 million.
Operating Cash Flow | 49.48M |
Capital Expenditures | -28,826 |
Free Cash Flow | 49.45M |
FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of 64.52% and 55.17%.
Gross Margin | 100.00% |
Operating Margin | 64.52% |
Pretax Margin | 59.25% |
Profit Margin | 55.17% |
EBITDA Margin | 63.46% |
EBIT Margin | 64.52% |
FCF Margin | 69.90% |
Dividends & Yields
OSE Immunotherapeutics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.97% |
Shareholder Yield | -22.97% |
Earnings Yield | 32.86% |
FCF Yield | 41.64% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
OSE Immunotherapeutics has an Altman Z-Score of 3.94.
Altman Z-Score | 3.94 |
Piotroski F-Score | n/a |